Darmstadt,
February
3rd 2015
Zedira has received further funding from the German Federal Ministry for Education and Research
(German abbreviation: BMBF). The project volume has been extended by € 1.0 Mio. so that the total
project value exceeds € 5.0 Mio. by now. The additional fundin
g will allow completing the development
of a drug candidate for „safe“ anticoagulation.
Zedira targets coagulation factor XIIIa (F13, plasma transglutaminase) using direct acting
peptidomimetic inhibitors including proof
-
of
-
concept studies in relevant animal models. Further, Zedira
continues the successful cooperation in the field of structur
al biology with the group of Prof. Gerhard
Klebe, Marburg University.
Dr. Martin Hils, managing partner, comments: „ We are more than happy to receive funding for this
cutting
-
edge project within this highly competitive program. The grant is a special ho
nor underlining our
successful drug discovery approach over the past decade.
Dr. Ralf Pasternack, managing partner, adds: „After licensing our lead project in the field of celiac
disease to Dr. Falk Pharma, the FXIII
-
project further strengthens our leadin
g international position in the
transglutaminase field. We are confident that our approach, due to the unique mode
-
of
-
action, will
p
rovide a safer therapeutic opportunity in anticoagulation for patients, doctors and payers.
________________________________________________________________________
__
This
press release is from
:
Zedira GmbH
Roesslerstr. 83
64293 Darmstadt
Germany
Phone:
+49 6151 3251
-
00
Fax:
+49 6151 3251
-
19
Web:
www.zedira.com
E
-
mail:
contact@zedira.com
© 201
5
, Zedira GmbH
Press
emitteilung
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.